Dr. Li Ge, Ph.D., is a Chinese-American businessman, the self-made billionaire Founder, Chairman, and former CEO of WuXi AppTec (HKSE: 2359 / SSE: 603259), a global contract research and manufacturing organization (CRDMO) for the pharmaceutical and biotech industries. His career is rooted in elite organic chemistry and biomedical research.

Li holds a Bachelor of Science degree in Chemistry from Peking University and a Ph.D. in Organic Chemistry from Columbia University. His career began with high-level research roles at Syntex/Roche in the U.S. His philosophical approach centers on technological integration and scale efficiency to accelerate drug discovery and development globally (the CRDMO model).

• WuXi AppTec (Founder & Chairman): The core publicly traded asset, a global leader in CRDMO (Contract Research, Development, and Manufacturing Organization) services for the pharmaceutical industry.
• Global Reach: The company has a massive global presence, providing services from drug discovery to clinical trials and manufacturing (employing 40,000+ people).
• Academic Background: He holds a Ph.D. in Organic Chemistry from Columbia University and a B.S. from Peking University.
• Investment Strategy: His success is built on vertical integration and scale manufacturing of essential research and drug components for major global pharma firms.

Dr. Li Ge returned to China and founded WuXi AppTec in 2000 (initially as WuXi PharmaTech). His strategic genius was his commitment to scale and efficiency in outsourcing, recognizing the structural trend of global pharmaceutical companies moving research and manufacturing to Asia. Under his leadership, WuXi AppTec became the world's largest CRDMO, successfully executing its IPO on the NYSE and subsequent dual listing on the HKSE and SSE.

His structural contribution is immense: providing the essential infrastructure and services that accelerate drug discovery for global pharmaceutical giants. His career is marked by controversy over geopolitical risk (facing scrutiny from U.S. regulators regarding its ties and data security). He stepped down as CEO in 2019, remaining Chairman. His wealth is secured by the colossal, long-term, stable profitability of the global pharmaceutical outsourcing sector.

Dr. Li Ge's social impact is structural, stemming from WuXi AppTec's role in accelerating drug discovery and development for global pharmaceutical companies, impacting public health worldwide. The company provides thousands of stable R&D and manufacturing jobs globally.

His personal philanthropy supports various community and educational initiatives. His structural contribution is tied to the successful industrialization and scale of the pharmaceutical outsourcing sector, emphasizing scientific rigor and efficiency.

Dr. Li Ge maintains the professional, composed style of a science-executive. His attire is consistently formal and high-quality, favoring tailored suits. His aesthetic reflects serious authority and stability, typical of a leader in the specialized biotech sector.

Residing in Shanghai, China, his luxury is the immense security and financial reward derived from his multi-billion dollar fortune. His life is dedicated to biotechnology innovation, scientific integrity, and the long-term pursuit of drug discovery.